Skip to main content

Atossa Therapeutics, Inc.

corporate_fare Company Profile

Atossa Therapeutics, Inc.

ATOS·NASDAQ·Life Sciences·CIK 0001488039

We are a clinical-stage biopharmaceutical company focused on developing innovative medicines for significant unmet medical needs in oncology, specifically breast cancer and other breast conditions. Our primary drug candidate is oral (Z)-endoxifen, a selective estrogen receptor modulator (SERM)/selective estrogen receptor degrader (SERM/D), which is currently in Phase 2 clinical development. We are exploring various indications for (Z)-endoxifen based on its pharmacological profile, including its potential to reduce the risk of and treat breast cancer, as well as other therapeutic areas. We hold U.S. and international patents for our proprietary (Z)-endoxifen and have numerous applications pending in the U.S. and other major countries. We anticipate patent protection for (Z)-endoxifen through at least November 17, 2038. Our business strategy involves advancing our programs through clinical studies, potentially with partners, and opportunistically acquiring or developing new programs in areas of high unmet medical need. (Z)-endoxifen is the most active metabolite of Tamoxifen, demonstrating substantially greater potency as an estrogen receptor antagonist compared to Tamoxifen and other approved SERMs. Unlike Tamoxifen, (Z)-endoxifen does not require metabolic activation via CYP2D6 and other liver enzymes to reach therapeutic concentrations, meaning its activity is not affected by patient-specific metabolic variability. This small-molecule oral agent is designed to directly inhibit estrogen receptor signaling, induce estrogen receptor degradation, and promote apoptosis in estrogen receptor positive (ER+) breast cancer cells. Preclinical and clinical data indicate that (Z)-endoxifen may inhibit clinically relevant ESR1 mutations linked to aromatase inhibitor resistance and may also inhibit protein kinase C beta one (PKCβ1), leading to downregulation of the AKT signaling pathway. We are evaluating (Z)-endoxifen in multiple settings within the ER+/human epidermal growth factor receptor 2 negative (HER2-) breast cancer treatment continuum, including neoadjuvant, adjuvant, and breast density reduction indications. An ongoing neoadjuvant clinical study has shown early signs of anti-tumor activity for (Z)-endoxifen.

Atossa Therapeutics, Inc. (NASDAQ:ATOS) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 26 items for ATOS at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-10, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 17 rated 8 or above. Recent SEC coverage for ATOS spans 10-Q, 8-K, 424B5, DEF 14A.

Recent high-impact activity:

  • Atossa Q3 Loss Narrows to $5.6M as Cash Falls to $20.6M
  • Atossa Q3: Cash Falls to $20.6M, Going Concern Reaffirmed as Burn Hits $24.7M
  • Atossa Executes CVR Deal: Shareholders Get 25% of Priority Review Voucher Proceeds
  • Atossa Q2 2026: Cash Burn Accelerates, Going Concern Warning, but Clinical Progress Continues
  • Atossa Reports Q2 2026 Results, Highlights (Z)-Endoxifen Progress in Rare Diseases and Breast Cancer

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$34.77M
Diluted EPS
-$4.04
Op. Cash Flow
-$29.76M
Free Cash Flow
-$29.79M
Operating Income
-$37.14M
Cash & Equivalents
$41.3M
Debt / Equity
0.00×
Shares Outstanding
8.61M sh
Source: 10-K · filed 2026-03-25 · accession 0001193125-26-124396

Short Interest & Short Volume

7.59 days to cover

FINRA reported short interest of 526,812 shares in ATOS as of the October 30, 2026 settlement, a 22.9% decrease from the prior period — about 7.6 days to cover at its recent average daily volume. On November 20, 2026, 60.4% of ATOS volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)526,812 shares as of October 30, 2026
Change vs prior period▼ 22.9%
Days to cover7.59 at avg daily volume of 69,379
Daily short volume (FINRA facilities)60.4% of 32,317 shares on November 20, 2026
5-day average short volume55.4%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

High risk

Filing-implied dilution signals for ATOS, detected from its recent SEC filings · based on capital-structure filings through 2026-06-12.

1 recent capital raiseATM program

Capital Raise Finalized · Offering Priced at Premium

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with A →
$1.65 +3.45% today
52-week range · as of 2026-11-10 $1.65 – $14.85
Market cap
$15.92M
Volume
48.9K (0.7× avg)
3-mo avg 72.7K
Live data · 2026-11-21 20:56 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed ATOS - Latest Insights

ATOS
Nov 10, 2026, 8:15 AM EST
Source: PR Newswire
Importance Score:
7
Price at Filing: $2.15
Real-time Price: $1.65 info
Change: -$0.500 (-23%) info
Market Cap: $15.917M info
ATOS
Nov 10, 2026, 8:00 AM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $2.15
Real-time Price: $1.65 info
Change: -$0.500 (-23%) info
Market Cap: $15.917M info
ATOS
Oct 09, 2026, 8:13 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $2.40
Real-time Price: $1.65 info
Change: -$0.750 (-31%) info
Market Cap: $15.917M info
ATOS
Aug 07, 2026, 8:45 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $2.38
Real-time Price: $1.65 info
Change: -$0.730 (-31%) info
Market Cap: $15.917M info
ATOS
Aug 07, 2026, 8:45 AM EDT
Source: PR Newswire
Importance Score:
7
Price at Filing: $2.38
Real-time Price: $1.65 info
Change: -$0.730 (-31%) info
Market Cap: $15.917M info
ATOS
Aug 07, 2026, 8:30 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $2.45
Real-time Price: $1.65 info
Change: -$0.800 (-33%) info
Market Cap: $15.917M info
ATOS
Jun 12, 2026, 9:16 AM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $2.55
Real-time Price: $1.65 info
Change: -$0.9001 (-35%) info
Market Cap: $15.917M info
ATOS
Jun 11, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $2.56
Real-time Price: $1.65 info
Change: -$0.910 (-36%) info
Market Cap: $15.917M info
ATOS
Jun 11, 2026, 8:00 AM EDT
Source: PR Newswire
Importance Score:
9
Price at Filing: $4.37
Real-time Price: $1.65 info
Change: -$2.72 (-62%) info
Market Cap: $15.917M info
ATOS
May 08, 2026, 8:45 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $5.62
Real-time Price: $1.65 info
Change: -$3.97 (-71%) info
Market Cap: $15.917M info
ATOS
May 08, 2026, 8:30 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $5.62
Real-time Price: $1.65 info
Change: -$3.97 (-71%) info
Market Cap: $15.917M info
ATOS
May 08, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $5.62
Real-time Price: $1.65 info
Change: -$3.97 (-71%) info
Market Cap: $15.917M info
ATOS
May 04, 2026, 8:34 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $5.55
Real-time Price: $1.65 info
Change: -$3.90 (-70%) info
Market Cap: $15.917M info
ATOS
Apr 16, 2026, 8:30 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $5.58
Real-time Price: $1.65 info
Change: -$3.93 (-70%) info
Market Cap: $15.917M info
ATOS
Mar 30, 2026, 5:30 PM EDT
Filing Type: DEF 14A
Importance Score:
8
Price at Filing: $4.71
Real-time Price: $1.65 info
Change: -$3.06 (-65%) info
Market Cap: $15.917M info
ATOS
Mar 25, 2026, 5:21 PM EDT
Filing Type: 10-K
Importance Score:
9
Price at Filing: $5.21
Real-time Price: $1.65 info
Change: -$3.56 (-68%) info
Market Cap: $15.917M info
ATOS
Mar 25, 2026, 5:20 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $5.21
Real-time Price: $1.65 info
Change: -$3.56 (-68%) info
Market Cap: $15.917M info
ATOS
Mar 20, 2026, 4:52 PM EDT
Filing Type: PRE 14A
Importance Score:
8
Price at Filing: $5.33
Real-time Price: $1.65 info
Change: -$3.68 (-69%) info
Market Cap: $15.917M info
ATOS
Feb 20, 2026, 4:22 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $4.21
Real-time Price: $1.65 info
Change: -$2.56 (-61%) info
Market Cap: $15.917M info
ATOS
Feb 20, 2026, 4:16 PM EST
Filing Type: 424B5
Importance Score:
8
Price at Filing: $4.21
Real-time Price: $1.65 info
Change: -$2.56 (-61%) info
Market Cap: $15.917M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets